Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2023-01-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug product. It is a short announcement (2574 characters) and does not contain financial data, regulatory certifications, or detailed report content. It is not an annual report, earnings release, or any detailed financial or governance report. It is an announcement of a significant company development related to product approval, which does not fit into categories like M&A, capital updates, or legal proceedings. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-01-05 English
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PRMT5 INHIBITOR SYH2045 OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug. It is not a financial report, earnings release, or regulatory filing related to financial performance. The document is short (2281 characters) and serves as a public announcement of a significant company development rather than a detailed report or filing. It does not contain financial data, management discussion, or regulatory certifications. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2023-01-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in issued shares, share options, and other share capital information for CSPC Pharmaceutical Group Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows a specific form (FF301) related to securities movements under the Exchange Listing Rules. The content focuses on share capital changes, share options, and confirmations related to securities, without any financial performance data or earnings information. This type of document is a regulatory filing reporting share capital movements and related confirmations, not a full financial report or earnings release. It fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-01-03 English
VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR THE TREATMENT OF OSTEOARTHRITIS OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a drug candidate ALMB-0166. It is an announcement of a regulatory milestone related to clinical trials and drug development, not a financial report, management change, or shareholder meeting material. The document is relatively short (3265 characters) and does not contain financial data, earnings, or detailed management discussion. It is not a report but an announcement of a significant event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-12-29 English
VOLUNTARY ANNOUNCEMENT - ORAL SMALL-MOLECULE CDK INHIBITOR SYH2043 OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug candidate. It is a short announcement (2143 characters) and does not contain financial data, detailed financial performance, or regulatory certifications. It is not a report, transcript, or detailed presentation but an update on a specific event related to the company's product development. The document is an announcement of a corporate event rather than a financial or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-12-28 English
VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial application (IND) by the U.S. FDA for a drug candidate NBL-020. It is an announcement of a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. The document is relatively short (3,254 characters) and serves as a public disclosure of a significant event rather than a detailed report or presentation. It does not contain financial data, voting results, or governance information. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.